X
[{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galecto to merge with onetime Celgene partner PharmAkea","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Galecto"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
PAT-1251
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: PAT-1251
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pharmakea therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
January 07, 2020